Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial.
Grünwald V, McKay RR, Buchler T, Eto M, Park SH, Takagi T, Zanetta S, Keizman D, Suárez C, Négrier S, Lee JL, Santini D, Bedke J, Staehler M, Kollmannsberger C, Choueiri TK, Motzer RJ, Burgents JE, Xie R, Okpara CE, Powles T. Grünwald V, et al. Among authors: okpara ce. Int J Cancer. 2024 Dec 30. doi: 10.1002/ijc.35288. Online ahead of print. Int J Cancer. 2024. PMID: 39739622
Sex hormone deficiency in male and female mice expressing the Alzheimer's disease-associated risk-factor TREM2 R47H variant impacts the musculoskeletal system in a sex- and genotype-dependent manner.
Pianeta R, Deosthale P, Sanz N, Kohler R, Okpara C, Arnett M, Asad I, Rogers A, Gerbig M, Essex A, Liu Z, Wallace JM, Plotkin LI. Pianeta R, et al. Among authors: okpara c. JBMR Plus. 2024 Nov 13;9(1):ziae144. doi: 10.1093/jbmrpl/ziae144. eCollection 2025 Jan. JBMR Plus. 2024. PMID: 39677924 Free PMC article.
Biomarker analyses from the phase 3 randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma.
Motzer RJ, Porta C, Eto M, Hutson TE, Rha SY, Merchan JR, Winquist E, Gurney H, Grünwald V, George S, Markensohn J, Burgents JE, Cristescu R, Sachdev P, Narita Y, Huang J, Zhao Z, Okpara CE, Minoshima Y, Choueiri TK. Motzer RJ, et al. Among authors: okpara ce. Ann Oncol. 2024 Dec 11:S0923-7534(24)04978-0. doi: 10.1016/j.annonc.2024.12.003. Online ahead of print. Ann Oncol. 2024. PMID: 39672382 Free article.
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
Marth C, Moore RG, Bidziński M, Pignata S, Ayhan A, Rubio MJ, Beiner M, Hall M, Vulsteke C, Braicu EI, Sonoda K, Wu X, Frentzas S, Mattar A, Lheureux S, Chen X, Hasegawa K, Magallanes-Maciel M, Choi CH, Shalkova M, Kaen D, Wang PH, Berger R, Okpara CE, McKenzie J, Yao L, Orlowski R, Khemka V, Gilbert L, Makker V; ENGOT-en9/LEAP-001 Investigators. Marth C, et al. Among authors: okpara ce. J Clin Oncol. 2024 Nov 26:JCO2401326. doi: 10.1200/JCO-24-01326. Online ahead of print. J Clin Oncol. 2024. PMID: 39591551
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011.
O'Donnell PH, Loriot Y, Csoszi T, Matsubara N, Shin SJ, Park SH, Atduev V, Gumus M, Karaca SB, Grivas P, de Wit R, Castellano DE, Powles T, Vuky J, Zhao Y, O'Hara K, Okpara CE, Franco S, Homet Moreno B, Żołnierek J, Siefker-Radtke AO. O'Donnell PH, et al. Among authors: okpara ce. Cancer. 2025 Jan 1;131(1):e35601. doi: 10.1002/cncr.35601. Epub 2024 Oct 28. Cancer. 2025. PMID: 39465550 Free PMC article.
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial.
Gaspar N, Hung GY, Strauss SJ, Campbell-Hewson Q, Dela Cruz FS, Glade Bender JL, Koh KN, Whittle SB, Chan GC, Gerber NU, Palmu S, Morgenstern DA, Longhi A, Baecklund F, Lee JA, Locatelli F, Márquez Vega C, Janeway KA, McCowage G, McCabe MG, Bidadi B, Huang J, McKenzie J, Okpara CE, Bautista F; OLIE Study Investigators. Gaspar N, et al. Among authors: okpara ce. JAMA Oncol. 2024 Dec 1;10(12):1645-1653. doi: 10.1001/jamaoncol.2024.4381. JAMA Oncol. 2024. PMID: 39418029 Free PMC article. Clinical Trial.
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study.
Chung HC, Saada-Bouzid E, Longo F, Yanez E, Im SA, Castanon E, Desautels DN, Graham DM, Garcia-Corbacho J, Lopez J, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Korakis I. Chung HC, et al. Among authors: okpara ce. Cancer. 2024 Oct 1;130(19):3278-3288. doi: 10.1002/cncr.35387. Epub 2024 Jun 21. Cancer. 2024. PMID: 39031824 Clinical Trial.
Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146.
Lee CH, Yogesh Shah A, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Pinto A, Gironés Sarrió R, Lee Cohn A, Asim Bilen M, Gunnestad Ribe S, Krohn Tennøe Ø, Richards D, Sweis RF, Courtright J, Heinrich D, Perini R, Kubiak P, Bock D, Okpara CE, Motzer RJ. Lee CH, et al. Among authors: okpara ce. Eur Urol. 2024 Nov;86(5):470-473. doi: 10.1016/j.eururo.2024.05.003. Epub 2024 May 21. Eur Urol. 2024. PMID: 38777648 No abstract available.
41 results